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1. Introduction
Stroke is the fourth leading causes of death in the United States. Annually, about 795,000 people
suffer from a stroke with about 140,000 people, or 1 in 19, dying each year due to stroke related
causes. [1] Between 1995-2005 overall stroke death rate fell 30%, even so, annual health care
related costs for stroke patients in 2012 were up to 38.6 billion. [1] It is well recognized that
cerebrovascular disease, specifically carotid atherosclerosis and subsequent stenosis, is a
leading cause of ischemic stroke, which makes up 87% of all strokes. Due to the significant
morbidity and mortality incurred by these patients the identification, management, and
treatment of carotid disease is of paramount importance.
2. Epidemiology
Cerebrovascular disease does not appear to affect all races and genders equally. In addition
to the usual cardiovascular risk factors of hypertension, diabetes, and smoking; age, gender
and race have also been shown to have an additive effect  on stroke risk.  In a study by
Rockman et al. they looked at a little over 3 million patients for evidence of carotid artery
stenosis.  After  controlling  for  gender  and  age  differences,  they  found that  there  was  a
marked variation in the prevalence of carotid artery stenosis with Native American subjects
having the highest prevalence followed by Caucasians. [2] Yet, based on CDC data, African
Americans’ risk of having a first stroke is nearly twice that of Caucasians. Overall, as would
be expected based on the prevalence of carotid disease, American Indians/Alaska Natives
are more likely to have a stroke than other groups. [1] Gender differences have also been
analyzed. In a large population based study carotid artery stenosis was detected in 3.8%
of men and 2.7% of women. [3] The reasons for these differences are thought in part to be
due  to  carotid  plaque  differences  between  men  and  women.  Sangiorgi  et  al.  evaluated
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plaque specimens from 457 patients and found that women, as compared to men of the
same age, had a lower prevalence of thrombotic plaques and a smaller area of necrotic core
and hemorrhage extension. Also, they found inflammatory features were less pronounced
in women as compared to men. [4] These results correlate with similar studies done for
evaluation of patients with coronary artery disease that showed that sex hormones seem
to  play  a  fundamental  protective  role  in  women.  [5,  6]  More  studies  still  need  to  be
conducted to determine the true role of gender in carotid artery disease. Age greater than
70 also appears to be a risk for stroke. In the Framingham study they found that seventy
year olds with hypertension and the presence one additional risk factor, such as diabetes
mellitus, cigarette smoking, cardiovascular disease, atrial fibrillation or electrocardiograph‐
ic abnormalities had an increase in 10 year stroke risk from an average of less than 9% in
women and 12.3% in men, to greater than 80%. [7].
3. Evaluation
Significant carotid artery atherosclerosis can put patients at a risk for stroke and/or transient
ischemic attack (TIA) making it imperative that at risk populations be accurately evaluat‐
ed and followed for disease progression. An ideal diagnostic imaging test could accurate‐
ly and reproducibly determine the degree of luminal stenosis as well as plaque morphology
in both a non-invasive and cost effective way. No one single imaging test encompasses all
these traits however several have been shown to have benefit in the diagnosis and work
up of carotid disease. At this time the most clinically effective first line imaging modality
for  identifying patients  with  carotid  artery  disease  is  duplex ultrasound (DUS).  In  2006
Wardlaw et al published a meta-analysis looking at non-invasive imaging tests either alone
or combined to determine if they could replace intra-arterial angiography for evaluation of
carotid  stenosis.  They  included  41  studies  and  found  that  contrast-enhanced  magnetic
resonance angiography (CEMRA) was the most accurate imaging modality for patients with
70-99% stenosis, however it was not cost-effective. Alternatively, DUS had a sensitivity of
0.89  and  specificity  of  0.84  for  carotid  stenosis  between  70-90%,  was  cost  effective  and
allowed  for  expedient  diagnosis  and  treatment  for  patients  recommending  it  as  the
diagnostic  test  of  choice.  In  patients  with  lower  degrees  of  stenosis  around 50-69% the
sensitivity of  DUS dropped to 0.36.  [8]  Conversely,  another meta-analysis  performed by
Jahromi et al found improved sensitivities and specificities of 0.98 and 0.88 for detecting
greater than 50% ICA stenosis;  and 0.94 and 0.90 respectively for detecting greater than
70% ICA stenosis. [9] Due to the potential risk of surgical intervention in patients with a
questionable  or  50-69%  stenosis,  a  subsequent  CEMRA  or  a  multi  detector  computed
tomographic  angiogram  (MDCTA),  is  highly  recommended.  [8]  Principle  limitations  of
ultrasound  remain  primarily  operator  experience.  Occasionally,  plaque  calcification,
shadowing  and  patient  body  habitus  can  also  prevent  accurate  assessment  of  stenosis.
Currently the indications for carotid duplex ultrasonography are cervical bruit, amaurosis
fugax, focal or cerebral transient ischemic attacks, drop attacks, or syncope.
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Figure 1. 71 year old male presenting with history of transient ischemic attack presenting as left arm numbness and
weakness. A. Ultrasound of the right internal carotid artery showing elevated velocities (arrow) up to 442 cm/s corre‐
lating with a greater than 70% stenosis by NASCET criteria. B. Same patient US of right proximal common carotid ar‐
tery with baseline velocities (arrow) 75.6 cm/s.
Figure 2. 79 year old male presented after transient ischemic attack. CTA obtained showing proximal right internal
carotid artery stenosis (greater than 70%) with heavy calcification (arrow). Also shown cross-sectional view of area of
greatest stenosis (dashed arrow).
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The degree of luminal stenosis has traditionally been the most important element when
considering the severity of carotid disease, however recently several studies have shown that
plaque structure and composition may be an additional marker for future cerebrovascular
events. [10, 11] DUS can provide only a basic view of plaque morphology, unable to consis‐
tently and accurately delineate characteristics of plaque vulnerability such as ulceration, a large
lipid necrotic ore, and a thin fibrous cap. [12, 13]. Gray-Weale developed a scale, later modified
by Geroulakos that identified 5 types of carotid artery plaques: type 1 (anechogenic with
echogenic fibrous cap), type 2 (predominately anechogenic but with echogenic areas repre‐
senting less than 25% of the plaque), type 3 (predominately hyperechogenic but with anecho‐
genic areas representing less than 25% of the plaque), type 4 (echogenic and homogeneous
plaque) and type 5 (unclassified plaques reflecting calcified plaques with areas of acoustic
shadowing which hide the deeper part of the arterial layers). [14, 15]. Using this type of
classification, a study by Polak et al. showed that asymptomatic elderly patients with a hypo-
echoic plaque have relative risk of ipsilateral ischemic stroke of 2.78, this was independent
from the degree of stenosis and other cardiovascular risk factors. [16]Another, similar inves‐
tigation by Mathiesen et al. found comparable results with the relative risk of ipsilateral
cerebrovascular events in patients with hypo-echoic plaques to be 3.52. [17] Nevertheless in
the Asymptomatic Carotid Surgery Trial (ACST), there was no evidence that the Gray-Weale
classification, or plaque echolucency, showed any influence on the risk of stroke over degree
of stenosis. [18]. The emergence of multi-detector computed tomographic angiography
(MDCTA) came with the increased advances of improved spatial and temporal resolution for
evaluating different arterial regions but also the ability to further differentiate plaque mor‐
phology between smooth, irregular and ulcerated surfaces. [19] Density of a plaque can also
be determined measured in Hounsfield units (HU). This can differentiate a “soft” plaque (<50
HU) which usually has a lipid-rich core and more likely to be associated with symptoms from
a “calcified” plaque (>120 HU) which generally remains asymptomatic. [20]. Even so, it seems
that MRA is probably the best modality for evaluating plaque morphology. Plaque compo‐
nents such as lipid cores, intraplaque hemorrhage, fibrotic tissue, fibrotic caps and calcifica‐
tions can all be evaluated with MRA to distinguish unstable plaques from stable ones. [21-23]
In a study by Sadat et al. MRA was used to evaluate plaque morphology in acute symptomatic,
recently symptomatic and asymptomatic patients. Results showed that MRA was clearly able
to identify plaque features including hemorrhage and thin fibrous caps in the acutely symp‐
tomatic group that varied from the recently symptomatic and asymptomatic groups. [23] The
use of MRA for further risk stratifying symptomatic patients or predicting high-risk asymp‐
tomatic patients, however requires further evaluation to determine its role in the evaluation
of carotid artery disease.
Even with all of the advances of DUS, MDCTA, and MDMRA, for many practitioners intra-
arterial digital subtraction arteriography (IADSA) still remains the gold standard for imaging
extra cranial and intracranial circulation. Although angiography allows for detailed evaluation
of the aortic arch, origins of the great vessels and the distal ICA, it is still an invasive imaging
modality potentially exposing patients to unnecessary complications and even possibly death.
Complications rates do vary among studies from as low as 0.4% in the Veterans Affair
Cooperative Study to 1.2% in the Asymptomatic Carotid Atherosclerosis Study and as high as
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12.5% in patients with severe bilateral carotid obstructive disease. [24-26]. IADSA can be
forgone in most situations where noninvasive diagnostic tests are available and now usually
only utilized in conjunction with planned carotid artery stenting.
3. Asymptomatic carotid stenosis
Patients with cerebrovascular disease can be divided into asymptomatic and symptomatic
disease. Patient’s with asymptomatic carotid disease generally come to the attention of
practitioners because they are found to have one or more risk factor for developing cerebro‐
vascular disease (age, diabetes mellitus, coronary artery disease, peripheral vascular disease,
hypertension, or hyperlipidemia) and/or signs on clinical exam, such as carotid bruit on
auscultation, that warrant further diagnostic evaluation. About 5% of the general population
over 65 years of age has an asymptomatic CAS of 50% or greater. [27-28]. This is increased in
patients with peripheral arterial disease up to 15% and in patients with abdominal aortic
aneurysms up to about 12%. [29] The overall annual risk of ipsilateral stroke for patients found
to have asymptomatic carotid stenosis that are treated medically is about 2%. Asymptomatic
carotid disease, in fact, seems to be a better indicator of generalized vascular disease than of
stroke risks. In this population the average annual non-stroke death rates are generally higher
than those of ipsilateral stroke with more than 50% of the non-stroke related deaths due to
ischemic heart disease and its complications. [30] For patients who are found to have carotid
disease, optimal medical management is the cornerstone to overall treatment. The goal of
medical therapy is to reduce overall cardiovascular events as well as stroke by a five pronged
attack including: treatment of hypertension, treatment of diabetes mellitus, treatment of lipid
abnormalities, smoking cessation, and antithrombotic treatment. As mentioned previously,
hypertension has been consistently found to be an independent risk factor for carotid artery
atherosclerosis with each 10-mm Hg increase in blood pressure resulting in an increase in risk
for stroke of 30-45%. Conversely each 10-mm Hg reduction in blood pressure in hypertensive
patients decreases risk for stroke by 33%. [31] Currently recommendations are for blood
pressures to be maintained less than 140 systolic and 90 diastolic. For patients with coronary
artery disease the relationship between lipid abnormalities and ischemic heart events has also
been clearly identified in the literature however at this time the relationship between elevated
cholesterol and stroke risk remain unclear. [32,33] Nevertheless, studies have shown that
patients with known atherosclerosis have demonstrated reduced stroke rates by 15-30% when
treated with lipid lowering therapy. [34] Smoking cessation is important for all patients with
vascular disease, and in carotid artery disease this is no different nearly doubling the overall
risk for stroke. [35] Finally both antithrombotic and anticoagulant therapy can also be utilized
for prevention in patients with carotid disease. There is more robust evidence for the use of
antithrombotic treatment for secondary prevention of recurrent stroke in symptomatic patients
than for prevention in asymptomatic patients, however it is still recommended that patients
who are at risk, or have known vascular disease, take a daily aspirin for prophylaxis. [36]
Anticoagulation with Coumadin is generally reserved for patients at risk for an embolic stroke
from atrial fibrillation and is not used as prophylaxis for asymptomatic or symptomatic carotid
disease. [37]
Evaluation and Treatment of Carotid Artery Stenosis
http://dx.doi.org/10.5772/57258
5
For asymptomatic patients who continue to have worsening carotid disease even with best
medical management the next step in treatment is to consider operative intervention. The
current recommendations from the Society for Vascular Surgery is for carotid endarterectomy
in asymptomatic patients with carotid stenosis of greater than or equal to 60% as long as the
expected combined stroke and mortality rate for the individual surgeon was not greater than
3%. [38] These recommendations are based on three major prospective, randomized trials the
Veterans Administration Asymptomatic Carotid Stenosis Study (VA ACS), the Asymptomatic
Carotid Atherosclerosis Study (ACAS), and the Asymptomatic Carotid Surgery Trial (ACST).
The VA ACS evaluated a total of 444 patients over an 8 year period randomizing them to a
surgical group (211) or and a medical group (233). Both groups were treated with aspirin and
best medical risk factor control. For the surgical arm, the 30-day mortality rate was 1.9% and
the incidence of stroke was 2.4% with a combined stroke and mortality rate of 4.3%. In total,
all neurologic events were 30 (14.2%). Conversely, the medical group had a total of 55 (23.6%)
neurologic events recorded. These findings were found to be statistically significant with a P
value of less than 0.006. [39] However, the study did not find any difference in overall survival
rates between groups. This trial gave credence that best medical treatment plus carotid
endarterectomy (CEA) would reduce stroke and TIAs versus medical treatment alone in
asymptomatic patients.
The ACAS was a NIH-funded randomized trial which included 1662 patients between the ages
of 40-79 years with greater than 60% asymptomatic stenosis. Patients were randomized to
optimal medical management versus CEA and medical management. The 30-day combined
mortality and stroke rate was 2.3%, which accounts for two preoperative deaths and seven
preoperative strokes making the actual stroke rate 1.3% and mortality rate 0.1%. After a mean
follow up of 2.7 years the overall 5-year risk for ipsilateral stroke, perioperative stroke and
death was 5.1% for surgical patients and 11% for the medical group (P=0.004). [40] An absolute
risk reduction for stroke and death in the surgical group was calculated to be 53%. [41] One
drawback of the ACAS study is that all patients with 60%-99% carotid stenosis were analyzed
together and there was no breakdown for event rates by deciles. Nevertheless, their results
again favored CEA plus medical management over medical management alone.
Finally a group of European investigators embarked on an additional randomized trial, ACST,
to try, in addition to validating CEA for asymptomatic patients with significant stenosis, to
identify a higher-risk group of patients. They randomized 3129 patients, both men and women,
with greater than 60% asymptomatic unilateral or bilateral carotid artery stenosis to CEA
versus best medical therapy. The found a 5 year stroke or death rate to be 6.4% versus 11.8 %
(p<0.0001) in the CEA versus medical group, respectively. Overall perioperative stroke or
death rate was 3.1%. These results were found to be significant for bother males and females
when analyzed separately [18].
4. Symptomatic carotid artery stenosis
When compared to asymptomatic patients the benefit of CEA with recent ipsilateral carotid
territory symptoms and moderated to severe carotid stenosis is much greater. In patients who
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experience a TIA or minor stroke the risk of subsequent stroke or death is very high, especially
during the first few days and weeks after an event. [42] Traditionally the mainstay of treatment
for symptomatic disease in these patients is surgical intervention with CEA. Recently there
has been literature advocating aggressive medical therapy alone may be adequate in certain
patients, preventing early stroke after TIA and reducing the need for urgent CEA. The Stroke
Prevention Aggressive Reduction of Cholesterol Levels (SPARCL) trail tested whether
treatment with atorvastatin reduced strokes in subjects with recent minor stroke or TIA. The
study included 4731 participants with a mean follow up of 4.9 years and found that high does
Atorvastatin use after TIA or stroke was associated with a 16% relative reduction in risk of
fatal or nonfatal stroke. Also patients treated were found to have a 56% reduction in later
carotid revascularization compared with placebo. Researchers postulated that the use of statins
might help stabilize the arterial wall decreasing events as well as reducing intraoperative
complications as well for patients who did proceed with surgery. [43,44] Merwick et al. also
evaluated early high dose statin use postulating that pretreatment at TIA onset would modify
early stroke risk. They found that non-procedural 7-day stroke risk was 3.8% with statin
treatment compared to 13.2% in those not pretreated. [45] Another study by Chimowitz et al.
evaluated a different medical treatment looking at recently symptomatic patients with
intracranial 79-99% stenosis who were treated with dual antiplatelet therapy versus percuta‐
neous transluminal angioplasty and stenting (PTAS) (gold standard for intracranial lesions).
This study found a 30-day rate of stroke or death was found to be 14.7% in the PTAS group
and 5.8% in the medical-management group. At one year follow this study concluded that
medical management with dual antiplatelet therapy was superior to PTAS and advocates belief
this data can be extrapolated to severe, symptomatic extra cranial disease as well. [46,47].
Several other older studies have compared the use of platelet antiaggregants with placebo in
treating patients with cerebral ischemia secondary to extra cranial atherosclerosis. [48-51]
These results however proved inferior to surgery, which was highlighted in the landmark
North American Symptomatic Carotid Endarterectomy Trial.
Two major randomized control  trials  have reported data to date advocating for CEA in
symptomatic patients with 50%-99% stenosis:  The North American Symptomatic Carotid
Endarterectomy Trial (NASCET) and Medical Research Council European Carotid Surgery Trial
(ECST). The NASCET trial was set up to evaluate two subsets of patients those with 70-99%
stenosis and those with 30-69% stenosis. In the high-grade stenosis group the 30-day opera‐
tive morbidity and stroke mortality rate for patients was 5%. In the surgical group at 2-year
follow-up the incidence of ipsilateral stroke was 9% compared to 26% in the medical treat‐
ment group. This difference represented an absolute risk reduction of 17% in favor of surgical
management and a relative risk reduction of 71% at the end of the 18-month follow up. Mortali‐
ty rates were also measured at the end of 18 months yielding 12% mortality rate in the medi‐
cal group compared to a significantly lower rate of 5% in the surgical group. [52,53]. The results
for the moderate stenosis group were also reported. The 30-day combined mortality, disa‐
bling stroke rate, and non-disabling stroke rate was 6.7%. At 5 year follow up in this group the
ipsilateral stroke rate was 22.2% in the medical patients and 16.7% in the surgical patients. [54]
The ECST trial was a European randomized control trial that enrolled patients over 10 years
almost concurrently with the NASCET trial. There were 2518 patients with nondisabling
ischemic stroke, TIA or retinal infarct due to a stenotic lesion in the ipsilateral carotid artery
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randomized to either medical management with aspirin or surgery. At 3 years, the risk of stroke
was found to be 26.5% in the medical group compared to 7% in the surgery group with an
absolute reduction of 14.9%. The actual incidence of ipsilateral stroke was 2.8% in the surgery
group versus 16.8% in the medical group. [55] ECST trial also evaluated gender, age, severity
of stenosis, plaque morphology, and time since last event. They found that risk of events
increased with age and with male gender. They did not find any benefit for surgery over
medical treatment in the mild stenosis group (10%-29%) unlike the severe stenosis group,
which showed a 6-fold reduction in subsequent strokes over 3 years. [56]
Based on these randomized studies there seems to be a consensus on which patients would
benefit from operative intervention after an ischemic event, however the timing of interven‐
tion has been much debated. The risk of recurrent stroke after TIA or minor stroke is the highest
within the first 7-10 days. According to a meta-analysis by Giles et al the risk of stroke after TIA
is 6.7% at 48 hours and 10% at 7 days with more than half of the strokes occurring within the
first 7 days doing so within the first 24 hours after the inciting event. [57,58] In another study
by Ois et al. the rate of recurrent stroke in symptomatic patients with greater then 50% stenosis
was determined to be 20.9% in the first 72 hours, 6.7% between 72 hours and 7 days and 3.7%
between 7 and 14 days. [59] These results support early intervention in the first 48 hours because
the risk of recurrent stroke appears to outweigh the operative risk in patients who are medical‐
ly stable and have relatively small or no infarcts on imaging studies. Alternatively, for a
completed stroke researchers advocate delayed surgical intervention for at least 4-6 weeks due
to the risk of converting an ischemic cerebral infarction into a hemorrhagic one. Giordano et al
reported on 49 CEAs done after a completed acute stroke. 27 of these were performed within 5
weeks of the event and 22 were done between 5 and 20 weeks. The early intervention group
had a morbidity and mortality of 18.5% compared to nothing for the later group. [60] These
results seem to corroborate with observations in both the NASCET and ECST trials.
5. Carotid artery stenting
Along with CEA, carotid artery stenting (CAS) has emerged as an alternative treatment
strategy for patients with carotid artery disease. Initially proponents of angioplasty and
stenting projected that this procedure could overcome the risks associated with CEA and
provide a minimally invasive alternative for patients. However at this time the utility of CAS
is highly debated with CEA remaining the standard of care in most asymptomatic and
symptomatic patients.
There have been very few studies that have specifically addressed CAS in asymptomatic
patients and most of the data available comes from high-risk registries which include patients
with lesions located at or above the level of C2, contralateral carotid occlusion, severe ulcera‐
tion and tandem intracranial stenosis, age over 80, active coronary artery disease or congestive
heart failure, and patient’s with “hostile necks” (immobile neck, previous irradiation, previous
surgery on the ipsilateral side or previous surgery on the contralateral side with vocal cord
paralysis). In the SAPPHIRE trial, which population included 70% asymptomatic high-risk
patients, their results found cumulative perioperative incidence of death, stroke, and MI of
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5.4% for CAS and 10.2% for CEA. [61] Their results found that CAS with cerebral protection
was not inferior to CEA. This study, however had several limitations including failure to
randomize >50% of patients, unaccounted for elevated incidence of perioperative stroke, and
possible reporting bias. The Carotid Revascularization Endarterectomy versus Stent Trial
(CREST) enrolled more than 1000 asymptomatic patients. Stroke and death rates after CAS
were 2.6% and 1.1% respectively with a difference between CAS and CEA in asymptomatic
patients for any periprocedural stroke being 2.5% versus 1.4%. [62-64] These results did not
show significant difference between CAS and CEA. The results from this study, however, were
based on procedures performed by highly experienced operators and have not been replicated
by other trials. [65]
 
(b) 
(c) (d) 
(a) 
Figure 3. 70 year old Male with a history of squamous cell carcinoma status post neck radiation and hemiglossectomy
found to have a 90% asymptomatic left common carotid artery stenosis. A: Angiogram of left common carotid artery
stenosis (arrow) B. Angiogrom showing cerebral protection device located in the left internal carotid artery (dashed
arrow) and stent placed in common carotid artery stenosis (black arrow). C. Post stent placement angioplasty balloon
inflated (arrow) D. Completion angiogram showing minimal residual stenosis after stent placed.
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For symptomatic patients several major randomized trials comparing CEA versus CAS have
been completed. These include the International Carotid stenting Study (ICSS), the Stent-
Supported Percutaneous Angioplasty of the Carotid Artery Versus Endarterectomy (SPACE)
trial, the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3s) trial, the Stenting and Angioplasty with Protection in Patients at high risk
for Endarterectomy (SAPPHIRE) trial and the Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREAST).
Trial Methods Results Conclusions
ICSS 1713 patient with
symptomatic stenosis >50%
CEA vs CEA
-Primary endpoint at 120
days was stroke, death or MI
-Primary endpoints:
Stroke: 7.7% CAS vs 4.1% CEA
Death: 2.3% CAS vs. 0.8% CEA
MI: 8.5% CAS vs. 5.2% CEA
-CAS higher rates of any stroke and all
cause death
-No significant difference between
groups in disabling stroke
SPACE European study 1196
patients with symptomatic
stenosis randomly assigned
180 days after TIA or stroke
to CAS vs. CEA
-Primary endpoint:
ipsilateral stroke or death at
30 days
-Stroke or Death:
-6.9% CAS vs. 6.5% CEA
-2 year follow up showed no
significant difference btw CAS
and CEA
- 9.5% CAS vs. 8.8% CEA
-failed to prove noninferiority of CAS
vs. CEA
-2 year restenosis more frequent in CAS
group
-10.7% vs 4.6%
EVA-3S French multicenter study
259 patients with severe
symptomatic stenosis >60%
CAS vs. CEA
-Evaluate hypothesis that
CAS in not inferior to CEA
(similar to SPACE)
-Primary endpoint: stroke or
death at 30 days
- Stroke and/or Death:
-9.6% CAS vs. 3.9% CEA
-RR 2.5
-4 year follow up Stroke
and/or Death
- 11.1% CEA vs. 6.2% CAS
-Stopped premature 2/2 deaths in CAS
group
-CEA needs to be safer before it can be
alternative to CEA
*CPD were optional
CREST RCT largest comparing CAS
vs. CEA in both symptomatic
and asymptomatic patients
-2502 enrolled; 47%
asymptomatic
- Death:
0.7% CAS vs. 0.3% CE
- Stroke:
4.1% CAS vs. 2.3% CEA
- MI:
1.1% CAS vs. 2.3% CEA
- Combined endpoints:
7.2% CAS vs. 6.8% CEA
-4 year follow up combined
endpoints:
-overall effectiveness and safety were
similar
-similar results male vs. female and
symptomatic vs. asymptomatic
-Periprocedural higher risk of stroke
with CAS and higher risk MI with CEA
-Subanalysis:
- No difference in primary
endpoint
based
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Trial Methods Results Conclusions
6.4% CAS vs. 4.7% CEA on symptomatic status
- Periprocedure stroke and
death
lower in CEA in symptomatic
SAPPHIRE Multicenter RCT comparing
CAS vs. CEA in both
symptomatic and
asymptomatic patients
-334 patients randomized
->70% of patients
asymptomatic
-CPD used in about 95%
-30 day Death stroke and MI:
5.4% CAS and 8.4% CEA
-1 year follow up death, stroke
and /or MI
-12.2% CAS vs. 20.1% CEA
- CAS with use of CPDs is not inferior to
CEA
Limitations:
-Mostly high risk patients enrolled
-747 patients enrolled only less then ½
randomized
-High periprocedural death rate
compared
to other trials
The ICSS was a randomized prospective, multicenter trial in 2010 composed of 1713 subjects
with recently symptomatic carotid artery stenosis greater than 50% who were randomized to
either CEA or CAS. At this time the 120-day reported results show that the CAS group had a
stroke, death, and MI rates of 7.7%, 2.3% and 8.5%, respectively. These were significantly
higher than rates in the CEA group, which were 4.1%, 0.8%, and 5.2% respectively. Also there
was an additional group that was analyzed by MRI. This analysis showed a greater number
of patients in the CAS group that had a new ischemic brain lesion compared to the surgery
counterpart. [66] The EVA-3S and SPACE trial had similar protocols as the ICSS trial. EVA-3S
study divided 259 patients to CAS with cerebral protection devices (CPD) and CEA. This study
found a significant, 2.5, higher risk for 30-day stroke and death in the CAS group than in the
CEA group (9.6% versus 3.9%). At 4 year follow-up the risk of periprocedural stroke or death,
and nonperiprocedural ipsilateral stroke was also higher in the CAS group (11.1% versus
6.2%). [67] This trial however was limited by operator experience were physicians were only
required to perform a minimum of two procedures with any device to qualify for enrollment.
In the SPACE trial, which was larger with 1196 patients, the rate of death or ipsilateral ischemic
stroke was 6.9% in the CAS group and 6.5% in the CEA group. At the end of two years results
showed a greater probability of recurrent carotid stenosis of more than 70% in the CAS group
Similar concerns were raised against the SPACE trial concerning the inexperience of the
operators. The inconsistent use of CPDs was another concern raised by opponents of this trial.
[68,69] Nevertheless, all three of these trials strongly favor CEA over CAS.
The SAPPHIRE trial previously mentioned was another one of the initial trials comparing CAS
versus CEA. This corporate sponsored study had a high proportion of patients who were
asymptomatic and at high risk for CEA. Results at one year found primary end-points of
ipsilateral stroke or death to be lower in the stenting group than in the CEA group (12.2%
versus 20.1%; P=0.5) supporting the superiority of CAS over CEA. The clinical correlation to
symptomatic patients however is unclear. The CREST trial, alternatively, was a randomized,
prospective, multicenter trial, which included 2502 patients. This trial had about an equal
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inclusion of symptomatic and asymptomatic patients. The primary endpoint of any stroke, MI
or death at 30-days were similar between CAS and CEA (6.8% versus 7.2%). Upon further
examination, patients in the CAS group had a lower rate of MI within 30 days (1.1% versus
2.3%) and patients in the CEA group had a lower 30-day rate of stroke (2.3% versus 4.1%). At
one-year follow up quality of life measurements were examined. Investigators found that
patients who had strokes reported significantly lower quality of life scores than those who had
MI or cranial nerve palsy. After one year, however, these measurements did not show any
significant difference. [62,64]The improved outcomes found in the CREST trial may reflect the
increased experience of vascular surgeons with endovascular procedures and stent placement
as well as the improvement in stents and device designs. This data supports that CAS is not
inferior to CEA and both procedures can be safely offered to patients for the treatment of
carotid artery disease.
Current overall recommendations by the Society of Vascular Surgery for intervention in
patients with carotid artery disease are:
1. For symptomatic patients with stenosis <50% or asymptomatic patients with stenosis <60%
optimal medical therapy is indicated
2. In patients who have >50% symptomatic lesions or >60% asymptomatic lesions CEA is
preferred to CAS
a. Asymptomatic patients >60% stenosis should be considered for CEA if that have a
3-5 year life expectancy and perioperative stroke/death rates are <3%
b. In patients with symptomatic stenosis >50% CEA is preferred, especially if patient is
>70, has a long lesion (>15mm), preocclusive stenosis, lipid-rich plaque that can be
completely removed, and have not had previous neck operations or radiation
3. CAS is preferred over CEA in symptomatic patients with >50% stenosis when
a. Patient has a tracheal stoma, scarred and fibrotic tissue from previous ipsilateral
surgery or radiation, prior cranial nerve injury, and lesions that extend proximal to
the clavicle or distal to the C2 vertebral body
b. Patient has severe uncorrectable CAD, CHF or COPD
4. Asymptomatic patients with >60% stenosis deemed “high risk” for CEA should be
managed with optimal medical therapy
a. Insufficient data to recommend CAS for asymptomatic patients that are normal or
high risk for CEA. [38]
Author details
Lindsay Gates and Jeffrey Indes
Yale University School of Medicine, New Haven CT, USA
Carotid Artery Disease - From Bench to Bedside and Beyond12
References
[1] Roger, VL, Go AS, Lloyd-Jones DM et al. "Heart disease and stroke statistics-2012 up‐
date: a report from the American Heart Association." Circulation 125.1 (2012): E2-220.
[2] Rockman C, Hoang H, Guo Y, et al. "The prevalence of carotid artery stenosis varies
significantly by race." J Vasc Surg 57 (2013): 327-337.
[3] Mathieson E, Joakkimsen O, Bonaa K, et al. "Prevalence of and risk factors associated
with carotid artery stenosis: the Troms Study." Cerebrovasc Dis 12 (2001): 44-51.
[4] Sangiorgi G, Roversi S, Zoccai G, et al. "Sex-related differences in carotid plaque fea‐
turesand inlammation." J Vasc Surg 2013 57 (2013): 338-344.
[5] Kardys I, Vliegenthart R, Oudkerk M, et al. "The female advantage in cardiovascular
diseae: do vascular beds contribute equally?" Am J Epidemiol 166 (2007): 403-412.
[6] Agrinier N, Cournot M, Dallongeville J, et al. "Menopause and modifiable coronary
heart disease risk factors: a population based study.." Maturitas 65 (2010): 237-243.
[7] Wolf P, D'Agostino R, Belanger A, et al. "Probability of Stroke: A risk profile from the
Framinham Study." Stroke 22 (1991): 312-318.
[8] Wardlaw J, Chappell F, Best J, et al. "Non-invasive imaging compared with intra-ar‐
terial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis."
Lancet 367 (2006): 1503-1512.
[9] Jahromi A, Cina C, Liu Y, et al. "Sensitivity and specificity of color duplex ultrasound
measurements in the estimation of the interval carotid artery stenosis: a systemic re‐
view and meta-analysis." J Vasc Surg 41 (2005): 962-972.
[10] Saba L, Sanfilippo R, Sannia S et al. "Association between carotid artery plaque vol‐
ume, composition, and ulceration: a retrospective assessment with MDCT.." AJR Am
J Roentgenol 199.1 (2012): 151-156.
[11] Saba L, Sanfilippo R, Sannia S, et al. "Imaging of the carotid artery." Atherosclerosis
220.2 (2012): 294-309.
[12] Hermus L, Van Dam G, Zeebregts C, et al. "Advanced carotid plaque imaging." Eur J
Vasc Endovasc Surg 39 (2010): 125-133.
[13] Tahara N, Imaizumi T, Virmani R, et al. "Clinical feasibility of molecular imaing of
plaque inflammation in atherosclerosis." J Nucl Med 50 (2009): 331-334.
[14] Gray-Weale A, Graham J, Burnett J, et al. "Carotid artery atheroma: comparison of
pre-operative B-mode ultrasound appearance with carotid endarterectomy specimen
pathology." J Cardiovasc Surg 29 (1988): 676.
Evaluation and Treatment of Carotid Artery Stenosis
http://dx.doi.org/10.5772/57258
13
[15] Geroulakos G, Ramaswani G, Nicolaides A, et al. "Characterization of symptomatic
and asymptomatic carotid plaques using high resolution real time ultrasound.." Br J
Surg 80 (1993): 2171-2177.
[16] Polak J, Shemanski L, O'Leary D, et al. "Hypoechoic plaque at US of the carotid ar‐
tery: an independent risk factor for incient stroke in adults aged 65 years or older.."
Radiology 208 (1998): 649-654.
[17] Mathiesen E, Bonaa K, Joakimsen O et al. "Echolucent plaques are associated with
high risk of ischemic cerebrovascular events in carotid stenosis: The Tromso Study."
Circulation 103 (2001): 2171-2175.
[18] Halliday A, Mansfield A, Marro J et al. "Prevention of disabling and fatal stroked by
successful carotid endarterectomy in patients without recent neurological symptoms:
a randomised controlled trial." Lancet 363 (2004): 1491-1502.
[19] DeWeert T, Cretier S, Groen H, et al. "Atherosclerotic carotid plaque surface mor‐
phology in the carotid bifurcation assessed with multi-detector computed tomogra‐
phy." Stroke 40 (2009): 1334-1340.
[20] De Weert T, Ouhlous M, Meijerling E, et al. "Characterisation and quantification of
atherosclerotic plaque components with multidetector computed tomography and
histopathological correlation." Arterioscler Thromb Vasc Biol 26 (2006): 2366.
[21] Yuan C, Mitsumori L, Beach K, et al. "Carotid atherosclerotic plaque: noninvasive
MR characterization and identification of vulnerable lesions.." Radiology 221.2
(2001): 285-299.
[22] Chu B, Kampschulte A, Ferguson M, et al. "Hemorrhage in teh atherosclerotic carotid
plaque: a high-resolution MRI study." Stroke 35.5 (2004): 1079-1084.
[23] Sadat U, Weerakkody R, Bowden D, et al. "Utility of high resolution MR imaging to
assess carotid plaque morphology: a comparisnon of acute symptomatic, recently
symptomatic and asymptomatic patients with carotid artery disease." Atherosclerosis
207 (2009): 434-439.
[24] Hobson R, Weiss D, Fields W et al. "Efficacy of carotid endarterectomy for asympto‐
matic carotid stenosis: the Veterans Affairs Cooperative Study Group.." N Engl J Med
328 (1993): 221-227.
[25] Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. "Endar‐
terectomy for asymptomatic carotid artery stenosis." JAMA 273 (1995): 1421-1428.
[26] Theodotou B, Whaley R, Mahaley et al. "Complication following transfemoral cere‐
bral l angiography for cerebral ischemia: report of 159 angiograms and correlation
with surgical risk.." Surg Neurol 28 (1987): 90-92.
[27] The European Carotid Surgery Trialists Collaborative Group. "Risk of stroke in the
distribution of an asymptomatic carotid artery." Lancet 345 (1995): 209-212.
Carotid Artery Disease - From Bench to Bedside and Beyond14
[28] Mineva P, Manchev I, Hadijiev D et al. "Prevalence and outcome of asymptomatic
carotid stenosis: a population-based ultrasonographic study." Eur J Neurol 9 (2002):
383-388.
[29] Goessens B, Visseren F, Algra A, et al. "Screening for asymptomatic cardiovascular
disease with noninvasive imaging in patients at high-risk and low-risk according to
the European Guidelines on Cardiovascular Disease Prevention: the SMART study."
J Vasc Surg 43 (2006): 525-532.
[30] Pickett C, Jackson J, Hemann B, et al. "Carotid bruits as a prognostic indicator of car‐
diovascular death and myocardial infarction: a meta-analysis." Lancet 371 (2008):
1587-94.
[31] Lawes C, Bennett D, Feigin V, Rodgers A. "Blood Pressure and stroke: an overview of
published reviews." Stroke 35 (2004): 1024.
[32] Iso H, Jacobs D, Wentworth D, et al. "Serum cholesterol levels and six-year mortality
from stroke in 350,977 men screened for the multiple risk factor intervention trial." N
Engl J Med 320 (1989): 904-910.
[33] Bots M, Elwood P, Nikitin Y, et al. "Total HDL cholesterol and risk of stroke. EURO‐
STROKE: a collaborative study among research centres in Europe." J Epidemiol
Comm Health 55 (2002): i19-24.
[34] Bucher H, Griffith L, Guyatt G. "Effect of HMGCoA Reductase Inhibitors on stroke.
A meta-analysis of randomized, controlled trials." Ann Intern Med 128 (1998): 89-95.
[35] Shinton R, Beevers G. "Meta-analysis of relation between cigarette smoking and
stroke." BMJ 298 (1989): 789-794.
[36] Wolff T, Miller T, KoS. "Aspirin for the primary prevention of cardiovascular events:
an update of the evidence for the U.S. Preventive services Task Force." Ann Intern
Med 150 (2009): 405-410.
[37] Mohr J, Thompson J, Lazar R, et al. "A comparision of warfarin and aspirin for the
prevention of recurrent ischemic stroke." N Engl J Med 345 (2001): 1444-1451.
[38] Ricotta J, AbuRahma A, Ascher E, et al. "Updated Society for Vascular Surgery
guideline for management of extracranial carotid disease." J Vasc Surg 54 (2011): e1-
e31.
[39] Veterans Administration: A Veterans Administration Cooperative Study. "Role of
carotid endarterectomy in asymptomatic carotid stenosis." Stroke 17 (1986): 535-539.
[40] Moore W, Young B, Baker W. "Surgical results: A justification of the surgeon selec‐
tion process for the ACAS Trial." J Vasc Surg 23 (1996): 323-328.
[41] Asymptomatic Carotid Artery Stenosis Group. "Study design for randomized pro‐
spective trial of carotid endarterectomy for asymptomatic atherosclerosis." Stroke 20
(1989): 844-849.
Evaluation and Treatment of Carotid Artery Stenosis
http://dx.doi.org/10.5772/57258
15
[42] P, Rothwell. "Medical and surgical management of symptomatic carotid stenosis." Int
J Stroke 1 (2006): 140-149.
[43] McFarlane, Sammy. "High-Dose Atorvastatin AFter Stroke or Transient Ischemic At‐
tack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL) investigators." J Cardiometab Syndr 3.1 (2008): 68-69.
[44] Goldstein L, Amarenco P, Zivin J, et al. "Statin treatment and stroke outcome in the
Stroke Prevention by Aggressvie Reduction in cholesterol Levels (SPARCL) trial."
Stroke 40.11 (2009): 3526-3531.
[45] Merwick A, Albers G, Arsava M, et al. "Reduction in early stroke risk in carotid
stenosis with transient ischemic attack associated with statin treatment." Stroke 44
(2013): Epud August 1 2013.
[46] Chimowitz M, Lynn M, Derdeyn C, et al. "Stenting versus aggressive medical thera‐
py for intracranial arterial stenosis." N Engl J Med 367.1 (2012): 93.
[47] Chaturvedi, S. "Aggressive Medical Therapy Alone is Adequate in Certain Patients
with Severe Symptomatic Carotid Stenosis." Stroke 44 (2013).
[48] S, Jonas. "Anticoagulant therapy in cerebrovascular disease: Review and meta-analy‐
sis." Stroke 19 (1988): 1043-1048.
[49] Canadian Cooperative Study Group. "A randomized trial of aspirin and sulfinpyra‐
zone in threatened strokes." N Engl J Med 299 (1978): 53.
[50] Bousser, et al. "AICLA controlled trial of aspirin and dipyridamole in the secondary
prevention of arteriothrombotic cerebral ischemia." Stroke 14 (1983): 5-14.
[51] Sorenson P, Pedersen H, Marquardsen J et al. "Acetylsalicylic Acid in the prevention
of stroke in patients with reversible cerebral ischemic attacks: A Danish cooperative
study." Stroke 14 (1983): 15-22.
[52] North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering
Committee. "North American Symptomatic Carotid Endarterectomy Trial: Methods,
patient characteristics, and progress." Stroke 22 (1991): 711-720.
[53] North American Symptomatic Carotid Endarterectomy Trial Collaborators. "Benefi‐
cial effect of carotid endarterectomy in symptomatic patients with high-grade carotid
stenosis." N Engl J Med 325 (1991): 445-453.
[54] Barnett M, Taylor D, Eliasziw M, et al. "Benefit of carotid endarterectomy in patients
with symptomatic moderate or severe stenosis." N Engl J Med 339 (1998): 1415-1425.
[55] European Carotid Surgery Trialists'Collaborative Group. "MRC European Carotid
Surgery Trial: Interim results for patients with severe (70-99%) or with mild (0-29%)
carotid stenosis." Lancet 337 (1991): 1235-1243.
Carotid Artery Disease - From Bench to Bedside and Beyond16
[56] Alqadri S, Qureshi A. "Treatment of Symptomatic Carotid Stenosis: Carotid Stent
Placement Versus Endarterectomy." Curr Atheroscler Rep 15 (2013): 345-350.
[57] Giles M, Rothwell P. "Risk of stroke early after transient ischemic attack: a systematic
review and meta-analysis." Lancet Neurol 6 (2007): 1063-1072.
[58] Chandratheva A, Mehta Z, Geraghty O, et al. "Population-based study of risk and
predictors of stroke in the first few hours after a TIA." Neurology 72 (2009):
1941-1947.
[59] Ois A, Cuadrado-Godia E, Rodriguez-Campello A, et al. "High risk of early neuro‐
logical recurrence in symptomatic carotid stenosis." Stroke 40 (2009): 2727-2731.
[60] Giordano J, et al. "Timing of carotid arterial endarterectomy after stroke." J Vasc Surg
2 (1985): 250.
[61] Yadav J, Wholey M, Kuntz R, et al. "Protected carotid-artery stenting versus endar‐
terectom in high risk patients." N Engl J Med 351 (2004): 1493-1501.
[62] Brott T, Hobson R, Howard G, et al. "Stenting verss endarterectomy for the treatment
of carotid-artery stenosis." N Engl J Med 363 (2010): 11-23.
[63] Bonati L, Dobson J, Algra A, et al. "Short-term outcome after stenting versus endar‐
terectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individu‐
al patient data." Lancet 376 (2010): 1062-1073.
[64] Silver F, Mackey A, Clark W, et al. "Safety of stenting and endarterectomy by symp‐
tomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial
(CREST)." Stroke 42 (2011): 675-680.
[65] Hobson R, Howard V, Roubin G, et al. "Credentialing of surgeions as interventional‐
ist for carotid artery stenting: experience from the lead-in phase of CREST." J Vasc
Surg 40 (2004): 952-957.
[66] Ederle J, Dobson J, Featherstone R, et al. "Carotid artery stenting compared with en‐
darterectomy in patients with symptomatic carotid stenosis (International Carotid
Stenting Study): an interim analysis of randomised controlled trial." Lancet 375
(2010): 985-997.
[67] Mas J, Chatellier G Beyssen B, et al. "Endarterectomy versus stenting in patents with
symptomatic severe carotid stenosis." N Engl J Med 19.2 (2007): 201-203.
[68] Ringleb P, Allenberg J, Bruckmann H, et al. "30-day result from the SPACE trial of
stent-protected angioplasty versus carotid endarterectomy in symptomatic patients:
a randomised non-inferiority trial." Lancet 368 (2006): 1239-1247.
[69] Stingele R, Berger J, Alfke K et al. "Clinical and angiographic risk factors for stroke
and death within 30 days after carotid endarterectomy and stent-protected angio‐
plasty: a subanalysis of the SPACE study." Lancet Neurol 7 (2008): 216-222
Evaluation and Treatment of Carotid Artery Stenosis
http://dx.doi.org/10.5772/57258
17

